News DeskDubai: A Dubai-based healthcare provider known for its diabetes-focused care has announced a major transformation, signaling a broader ambition to tackle the growing burden of metabolic disease across the region and beyond.
GluCare.Health, founded in 2020, revealed this week that it will now operate under the name Metabolic, a move executives say reflects its evolution from a specialist diabetes clinic into a comprehensive metabolic health platform. The rebrand comes amid mounting scientific consensus that metabolic syndrome is not a single condition, but a cluster of interconnected risks contributing to diabetes, obesity, cardiovascular disease, fatty liver disease, hormonal disorders, and chronic inflammation.
Company leaders say the shift represents more than a name change. It marks the rollout of a hybrid care model designed to continuously track patient health, identify risks earlier, and coordinate treatment across multiple specialties.
At the heart of the new platform is Metabolic OS, described by the company as a care operating system that combines advanced diagnostics, remote monitoring, and artificial intelligence–supported clinical workflows. The system is intended to support clinicians rather than replace them, integrating data streams into actionable care plans between traditional appointments.
“Over the past five years, we’ve built what we believe healthcare has long needed — an operating system for metabolic risk,” said Ali Hashemi, CEO and Co-Founder. “Instead of disconnected apps, devices, and tests, the goal is a unified model where data informs decisions and decisions lead to measurable outcomes, while keeping patients engaged outside clinic walls.”
Dr. Ihsan Almarzooqi, Managing Director and Co-Founder, highlighted the regional urgency driving the expansion. “A significant proportion of people living with type 2 diabetes in the UAE remain uncontrolled, and the same underlying metabolic drivers are contributing to obesity, cardiovascular disease, and hormonal conditions,” he said. “The technology to intervene earlier now exists, but it must be embedded within coordinated care pathways.”
While diabetes care remains central to the organization’s services, the newly branded Metabolic platform now spans a wider clinical footprint. These include endocrinology, cardiology, thyroid care, women’s and men’s health, obesity management, preventive risk assessment, sleep-related metabolic disorders, bone health, ophthalmology, and lifestyle-based clinical pathways.
The company says the platform’s approach centers on creating a longitudinal view of each patient, integrating biomarkers, imaging results, vital signs, and behavioral data to support proactive care. Multidisciplinary teams, continuous monitoring, and AI-enabled risk stratification are positioned as key components of the model.
According to data published by the company in 2025, patients enrolled in its programs recorded improvements across several cardiometabolic indicators. Reported outcomes included reductions in HbA1c of up to 2.3 percentage points, average weight loss approaching 10 percent within three months, declines in waist circumference of roughly 15 percent, triglyceride reductions nearing 30 percent, and modest improvements in systolic blood pressure. Greater gains were observed among patients demonstrating high levels of digital engagement. The organization also reported progress in preserving muscle mass among individuals using GLP-1 therapies.
As part of the restructuring, the GluCare.Health brand will continue within the organization as its research and insights arm, supporting clinical studies, publications, and ongoing development of the care model.
Headquartered in Dubai, Metabolic is now preparing for international growth, with clinic launches planned in the United Kingdom in 2026 and the United States in 2027.
